OptimizeRx (NASDAQ:OPRX) Stock Rating Lowered by Wall Street Zen

OptimizeRx (NASDAQ:OPRX) was downgraded by Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

Other research analysts have also issued research reports about the company. Stephens decreased their target price on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Monday, November 17th. Citigroup reaffirmed an “outperform” rating on shares of OptimizeRx in a report on Friday, October 10th. Citizens Jmp lifted their target price on shares of OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Roth Capital restated a “buy” rating on shares of OptimizeRx in a research report on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and an average price target of $16.88.

OptimizeRx Trading Down 2.8%

Shares of OptimizeRx stock opened at $14.24 on Friday. The firm has a 50-day simple moving average of $17.58 and a two-hundred day simple moving average of $15.84. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.05 and a current ratio of 3.05. OptimizeRx has a fifty-two week low of $3.99 and a fifty-two week high of $22.25. The company has a market cap of $265.43 million, a P/E ratio of 36.62 and a beta of 1.10.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Thursday, November 6th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.17. OptimizeRx had a return on equity of 6.37% and a net margin of 0.03%.The company had revenue of $26.07 million during the quarter, compared to analysts’ expectations of $23.83 million. As a group, equities analysts predict that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

Insider Transactions at OptimizeRx

In other OptimizeRx news, CEO Stephen L. Silvestro sold 1,620 shares of the firm’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total value of $30,375.00. Following the completion of the sale, the chief executive officer directly owned 188,916 shares of the company’s stock, valued at $3,542,175. This trade represents a 0.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On OptimizeRx

Hedge funds have recently modified their holdings of the company. Nisa Investment Advisors LLC increased its position in OptimizeRx by 600.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after purchasing an additional 1,818 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of OptimizeRx in the 2nd quarter valued at approximately $44,000. BNP Paribas Financial Markets increased its holdings in shares of OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of OptimizeRx during the 1st quarter worth approximately $99,000. Finally, Virtu Financial LLC purchased a new stake in shares of OptimizeRx during the 1st quarter valued at approximately $112,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.